In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Angiotech buys Quill to integrate suture business

This article was originally published in The Gray Sheet

Executive Summary

Angiotech acquires Quill Medical for $40 mil. May 25. Vertical integration of minimally invasive wound closure device maker Quill follows closely on the heals of Angiotech's purchase of Quill distributor American Medical Instruments. AMI was acquired by Angiotech in March for $785 mil. as part of a strategy to expand direct device sales and become less reliant on royalty-based partnerships. AMI's Surgical Specialties unit markets privately held Quill's 510(k)-cleared Contour Thread, a self-anchoring polypropylene suture technology for minimally invasive "face lift" procedures, under a 2004 agreement. Angiotech plans to develop the Contour technology for use in additional aesthetic and general surgical applications. Angiotech notes it does not expect Quill to "materially impact" corporate sales in 2006 or 2007. With the AMI purchase, Angiotech forecasts total 2006 revenue of $325 mil. to $335 mil. - including nine months of AMI sales - and total 2007 revenue of $400 mil. to $425 mil...

You may also be interested in...

GNC In Rough Seas From COVID-19 Pandemic; Vitamin Shoppe Safe In Port Under New Owner

GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.

QUOTED. 7 April 2020. Surendar Magar.

California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.

EMA's Decision On Ranitidine Remaining Available Could Come At End Of April

Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts